Asymmetric Biomimetic Transamination of Trifluoromethyl Ketones

In the presence of chiral pyridoxamine 4b as the catalyst and 2,2-diphenylglycine (3) as the amine source, asymmetric biomimetic transamination of trifluoromethyl ketones produces optically active α-trifluoromethyl amines 6 in 81-98% yields with 88-95% ee's under mild conditions.

Total Synthesis of Denigrin E and Its Oxidative Conversion into Co-occurring Metabolite Denigrin D

An unambiguous, six-step total synthesis of denigrin E (5) from anisaldehyde 22 has been achieved, confirming the structure of this marine natural product. On treatment with t-BuOOH/Mo(CO)₆, compound 5 undergoes a unique and possibly biogenetically relevant oxidative rearrangement to generate the co-occurring metabolite denigrin D (4), which is obtained in 61% yield.

Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione Derivative Inhibits d-Dopachrome Tautomerase Activity and Suppresses the Proliferation of Non-Small Cell Lung Cancer Cells

The homologous cytokines macrophage migration inhibitory factor (MIF) and d-dopachrome tautomerase (d-DT or MIF2) play key roles in cancers. Molecules binding to the MIF tautomerase active site interfere with its biological activity. In contrast, the lack of potent MIF2 inhibitors hinders the exploration of MIF2 as a drug target. In this work, screening of a focused compound collection enabled the identification of a MIF2 tautomerase inhibitor R110. Subsequent optimization provided inhibitor 5d with an IC₅₀ of 1.0 μM for MIF2 tautomerase activity and a high selectivity over MIF. 5d suppressed the proliferation of non-small cell lung cancer cells in two-dimensional (2D) and three-dimensional (3D) cell cultures, which can be explained by the induction of cell cycle arrest via deactivation of the mitogen-activated protein kinase (MAPK) pathway. Thus, we discovered and characterized MIF2 inhibitors (5d) with improved antiproliferative activity in cellular models systems, which indicates the potential of targeting MIF2 in cancer treatment.